Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results forOREX
0.410
-0.018 (-4.25%)
After Hours: 0.410 0.000 (0.00%)
May 26, 4:00pm GMT-4  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.41 - 0.43
52 week 0.35 - 5.19
Open 0.43
Vol / Avg. 663,050.00/2.30M
Mkt cap 59.99M
P/E     -
Div/yield     -
EPS -0.54
Shares 145.54M
Beta 2.26
Inst. own 77%
Aug 4, 2016
Q2 2016 Orexigen Therapeutics Inc Earnings Release (Estimated) - 4:00pm GMT-4 - Add to calendar
Jul 8, 2016
Orexigen Therapeutics Inc Annual Shareholders Meeting - 1:00pm GMT-4 - Add to calendar
Jun 8, 2016
Orexigen Therapeutics Inc Annual Shareholders Meeting (Estimated) - 1:00pm GMT-4 - Add to calendar
May 10, 2016
Orexigen Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 4, 2016
Q1 2016 Orexigen Therapeutics Inc Earnings Call - Webcast
May 4, 2016
Q1 2016 Orexigen Therapeutics Inc Earnings Release
Mar 15, 2016
Orexigen Therapeutics Inc to Discuss Acquisition of U.S. Rights to Contrave and the Central and Eastern European Partnership with Valeant Pharmaceuticals International, Inc. Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -444.03% -280.82%
Operating margin -463.32% -245.53%
EBITD margin - -244.61%
Return on average assets -29.33% -30.57%
Return on average equity -405.09% -246.53%
Employees 67 -
CDP Score - -

Address

3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Interim Chief Financial Officer, Director
Age: 55
Bio & Compensation  - Reuters
Thomas P Lynch Executive Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Thomas R Cannell Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Executive Vice President - Product Development
Age: 46
Bio & Compensation  - Reuters
Peter Flynn Ph.D. Senior Vice President, Head - Development, Regulatory Affairs and Safety
Bio & Compensation  - Reuters
Toni Foster Senior Vice President - Project Management Office and Clinical Operations
Bio & Compensation  - Reuters
Chris Hazuka Acting General Counsel
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 50
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 74
Bio & Compensation  - Reuters